Citations

Showing 10 of 108083 citations.

Bacterial Virulence and Prevention for Human Spaceflight
Wazir, Hakim Ullah, Narang, Pooja, Silvani, Giulia, Mehner, Christine , Poole, Kate , Burke, Catherine , Chou, Joshua , Wazir, Hakim , Silvani, Giulia

Mayo Clinic

Life | February 28, 2023 | Volume: 13 | Issue: 3 | Pages: 656

10.3390/life13030656 | PMID 36983812 Get It

With the advancement in reusable rocket propulsion technology, space tourist trips into outer space are now becoming a possibility at a cost-effective rate. As such, astronauts will face a host of health-related challenges, particularly on long-duration space missions where maintaining a balanced healthy microbiome is going to be vital for human survival in space exploration as well as mission success. The human microbiome involves a whole list of micro-organisms that reside in and on the human host, and plays an integral role in keeping the human host healthy. However, imbalances in the microbiome have been directly linked to many human diseases. Research findings have clearly shown that the outer space environment can directly affect the normal microbiome of astronauts when the astronaut is exposed to the microgravity environment. In this study, we show that the simulation of microgravity on earth can mimic the outer space microgravity environment. Staphylococus aureus (S. aureus) was chosen for this study as it is an opportunistic pathogen, which is part of the normal human skin microflora and the nasal passages. This study’s results show that S. aureus proliferation was significantly increased under a microgravity environment compared to Earth’s gravity conditions, which complements previous work performed on bacteria in the outer space environment in the International Space Station (ISS). This demonstrates that this technology can be utilised here on Earth to mimic the outer space environment and to study challenging health-related questions. This in return saves us the cost on conducting experiments in the ISS and can help advance knowledge at a faster rate and produce countermeasures to mitigate the negative side effects of the hostile outer space environment on humans.
Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2
Nguyen, Tina , Lau, Anthony , Bier, Julia , Cooke, Kristen C. , Lenthall, Helen , Ruiz‐Diaz, Stephanie , Avery, Danielle T. , Brigden, Henry , Zahra, David , Sewell, William A. , Droney, Luke , Okada, Satoshi , Asano, Takaki , Abolhassani, Hassan , Chavoshzadeh, Zahra , Abraham, Roshini S. , Rajapakse, Nipunie , Klee, Eric W. , Church, Joseph A., Williams, Andrew , Wong, Melanie , Burkhart, Christoph , Uzel, Gülbû , James, David E. , Deenick, Elissa K. , Croucher, David R , James, David E , Ma, Cindy S , Brink, Robert , Tangye, Stuart G , Deenick, Elissa K , Zahra, David

Mayo Clinic

Journal of Experimental Medicine | February 28, 2023 | Volume: 220 | Issue: 6 | Pages: No page available

10.1084/jem.20221020 | PMID 36943234 Get It

Heterozygous loss-of-function (LOF) mutations in PIK3R1 (encoding phosphatidylinositol 3-kinase [PI3K] regulatory subunits) cause activated PI3Kδ syndrome 2 (APDS2), which has a similar clinical profile to APDS1, caused by heterozygous gain-of-function (GOF) mutations in PIK3CD (encoding the PI3K p110δ catalytic subunit). While several studies have established how PIK3CD GOF leads to immune dysregulation, less is known about how PIK3R1 LOF mutations alter cellular function. By studying a novel CRISPR/Cas9 mouse model and patients’ immune cells, we determined how PIK3R1 LOF alters cellular function. We observed some overlap in cellular defects in APDS1 and APDS2, including decreased intrinsic B cell class switching and defective Tfh cell function. However, we also identified unique APDS2 phenotypes including defective expansion and affinity maturation of Pik3r1 LOF B cells following immunization, and decreased survival of Pik3r1 LOF pups. Further, we observed clear differences in the way Pik3r1 LOF and Pik3cd GOF altered signaling. Together these results demonstrate crucial differences between these two genetic etiologies.
Current opinions on DGF management practices: A survey of the United States and Canada
Hippen, Benjamin , Gill, John S. , Heilman, Raymond L. , Stewart, Darren , Reddy, Kunam S. , Mohan, Sumit , Wiseman, Alexander C. , Cooper, Matthew , Jadlowiec, Caroline , Hippen, Benjamin , Heilman, Raymond , Mohan, Sumit , Cooper, Matthew , Jadlowiec, Caroline C.

Mayo Clinic

Clinical Transplantation | February 27, 2023 | Volume: 37 | Issue: 5 | Pages: No page available

10.1111/ctr.14949 | PMID 36849704 Get It

Abstract Introduction Significant center‐to‐center variation in attitudes and management of delayed graft function (DGF) remains common. Methods A survey to describe current DGF practices was developed by workgroup members sponsored by the National Kidney Foundation (NKF) and was distributed to both the NKF DGF workgroup members, kidney transplant program directors and the transplant community within the United States and Canada. Seventy‐one percent of NKF workgroup members completed the survey along with 70 unique the United States and three Canadian kidney transplant programs. All Organ Procurement and Transplantation Network (OPTN) regions were represented. Results DGF was reported to occur at rate of 20%–40% for most centers with 3.9% indicating their incidence to be >60%. Most centers reported longer hospital lengths of stay and more frequent outpatient visits. Despite the commonality of DGF, only half of centers reported having an established protocol to manage DGF. Kidney allograft biopsies were the only consistent DGF management strategy observed, although use of machine perfusion was also heavily favored. Other DGF management strategies voiced by a minority included having established outpatient practices to care for DGF patients and administering outpatient community‐based hemodialysis. Conclusion Although approximately a third of survey responders indicated that risk of DGF played a role in their willingness to accept organs, most did not feel that increased cost or clinical impact on outcomes was a deterrent. Future strategies, including broader sharing of best practices, redefining terminology specific to DGF, the establishment of DGF dialysis guidelines and improving access to machine perfusion across OPOs may help reduce discard and improve utilization of kidneys at risk for DGF.
Ceramide concentrations in liver, plasma, and very low‐density lipoproteins of humans with severe obesity
Lytle, Kelli A. , Chung, Jin Ook , Bush, Nikki C., Triay, Jessica, Jensen, Michael D.

Mayo Clinic

Lipids | February 27, 2023 | Volume: 58 | Issue: 3 | Pages: 107-115

10.1002/lipd.12367 | PMID 36849669 Get It

AbstractWe investigated the relationships between ceramide species concentrations in liver, plasma and very low‐density lipoproteins (VLDL) particles of humans with obesity as well as the relationships between hepatic fat content and hepatic ceramide concentrations and proportional distribution. Twenty‐five obese (body mass index >35 kg/m2) adults participated in this study. Plasma, VLDL and hepatocellular ceramide concentrations were measured by liquid chromatography/tandem mass spectrometry. The proportionate distribution of measured ceramide species differed between liver, whole plasma and the VLDL fraction. We found significant, positive correlations between the proportion of C14:0, C18:0, C20:0 and C24:1 ceramide in the liver and whole plasma (γ = 0.491, p = 0.013; γ = 0.573, p = 0.003; γ = 0.479, p = 0.015; γ = 0.716, p = 0.00006; respectively). In contrast, only the proportional contribution of C24:1 ceramide correlated positively between VLDL and liver (γ = 0.425, p = 0.013). The percent hepatic fat correlated positively with the proportion of C18:1, C18:0 and C20:0 hepatic ceramides (γ = 0.415, p = 0.039; γ = 0.426, p = 0.034; γ = 0.612, p = 0.001; respectively), but not with total hepatic ceramide concentration. The proportions of whole plasma ceramide subspecies, especially C14:0, C18:0, C20:0 and C24:1chain length, are reflective of those of hepatic ceramide subspecies in obese humans; these appear to be markers of hepatic ceramide species composition.
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine
Lumish, Melissa , Thackray, Jennifer , Gian, Richard Kinh , Caudle, Kelly E. , Amstutz, Ursula , Schwab, Matthias , Diasio, Robert B. , Cercek, Andrea , Do, Richard Kinh Gian , Cercek, Andrea , Diasio, Robert B , Schwab, Matthias , Jarnagin, William R.

Mayo Clinic

JCO Precision Oncology | February 27, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.22.00442 | PMID 36848609 Get It

Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop
Go, Alan S. , Al‐Khatib, Sana M. , Desvigne‐Nickens, Patrice , Bansal, Nisha , Bushnell, Cheryl , Fang, Margaret C. , Freeman, James V. , Gage, Brian F. , Hanke, Thorsten , Singer, Daniel E. , Thomas, Kevin L. , Hills, Mellanie True , Turakhia, Mintu P. , Zieman, Susan J., Cooper, Lawton S. , Benjamin, Emelia J. , Bushnell, Cheryl D , Lopes, Renato D , Noseworthy, Peter A , Reddy, Vivek Y , Singer, Daniel E , Thomas, Kevin L , True Hills, Mellanie , Turakhia, Mintu P , Cooper, Lawton S , Benjamin, Emelia J , Freeman, James V , Al-Khatib, Sana M. , Hylek, Elaine M. , Lópes, Renato D. , Noseworthy, Peter A. , Reddy, Vivek Y.

Mayo Clinic

Stroke | February 27, 2023 | Volume: 54 | Issue: 3 | Pages: No page available

10.1161/strokeaha.121.038273 | PMID 36848427 Get It

Atrial fibrillation (AF) is one of the strongest risk factors for ischemic stroke, which is a leading cause of disability and death. Given the aging population, increasing prevalence of AF risk factors, and improved survival in those with cardiovascular disease, the number of individuals affected by AF will continue increasing over time. While multiple proven stroke prevention therapies exist, important questions remain about the optimal approach to stroke prevention at the population and individual patient levels. Our report summarizes the National Heart, Lung, and Blood Institute virtual workshop focused on identifying key research opportunities related to stroke prevention in AF. The workshop reviewed major knowledge gaps and identified targeted research opportunities to advance stroke prevention in AF in the following areas: (1) improving risk stratification tools for stroke and intracranial hemorrhage; (2) addressing challenges with oral anticoagulants; and (3) delineating the optimal roles of percutaneous left atrial appendage occlusion and surgical left atrial appendage closure/excision. This report aims to promote innovative, impactful research that will lead to more personalized, effective use of stroke prevention strategies in people with AF.
Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020
Perera, Nirosha D. , Bellomo, Tiffany R. , Schmidt, Walker M. , Litt, Henry K. , Shyu, Margaret , Stavins, MaKenna A. , Wang, Max , Bell, Alexander , Saleki, Massoud , Wolf, Katherine I. , Ionescu, Ruxandra , Tao, Jacqueline J. , OʼKeefe, Ryan , Pun, Matthew , Takasugi, Jordan M., Turner, Brandon E. , Mahipal, Amit , Wang, Max M , Ji, Sunjong , O'Keefe, Ryan M , Pun, Matthew , Steinberg, Jecca R , Turner, Brandon E , Mahipal, Amit , Bell, Alexander , Ionescu, Ruxandra, Ji, Sunjong , Go, Ronald S.

Mayo Clinic

The Oncologist | February 27, 2023 | Volume: 28 | Issue: 6 | Pages: 510-519

10.1093/oncolo/oyad009 | PMID 36848266 Get It

Abstract Background Female underrepresentation in oncology clinical trials can result in outcome disparities. We evaluated female participant representation in US oncology trials by intervention type, cancer site, and funding. Materials and Methods Data were extracted from the publicly available Aggregate Analysis of ClinicalTrials.gov database. Initially, 270,172 studies were identified. Following the exclusion of trials using Medical Subject Heading terms, manual review, those with incomplete status, non-US location, sex-specific organ cancers, or lacking participant sex data, 1650 trials consisting of 240,776 participants remained. The primary outcome was participation to prevalence ratio (PPR): percent females among trial participants divided by percent females in the disease population per US Surveillance, Epidemiology, and End Results Program data. PPRs of 0.8-1.2 reflect proportional female representation. Results Females represented 46.9% of participants (95% CI, 45.4-48.4); mean PPR for all trials was 0.912. Females were underrepresented in surgical (PPR 0.74) and other invasive (PPR 0.69) oncology trials. Among cancer sites, females were underrepresented in bladder (odds ratio [OR] 0.48, 95% CI 0.26-0.91, P = .02), head/neck (OR 0.44, 95% CI 0.29-0.68, P < .01), stomach (OR 0.40, 95% CI 0.23-0.70, P < .01), and esophageal (OR 0.40 95% CI 0.22-0.74, P < .01) trials. Hematologic (OR 1.78, 95% CI 1.09-1.82, P < .01) and pancreatic (OR 2.18, 95% CI 1.46-3.26, P < .01) trials had higher odds of proportional female representation. Industry-funded trials had greater odds of proportional female representation (OR 1.41, 95% CI 1.09-1.82, P = .01) than US government and academic-funded trials. Conclusions Stakeholders should look to hematologic, pancreatic, and industry-funded cancer trials as exemplars of female participant representation and consider female representation when interpreting trial results.
Emerging Roles of Endothelial Nitric Oxide in Preservation of Cognitive Health
Katušić, Zvonimir S. , d’Uscio, Livius V. , He, Tongrong , Katusic, Zvonimir S

Mayo Clinic

Stroke | February 27, 2023 | Volume: 54 | Issue: 3 | Pages: 686-696

10.1161/strokeaha.122.041444 | PMID 36848426 Get It

eNOS (endothelial nitric oxide synthase) is critically important enzyme responsible for regulation of cardiovascular homeostasis. Under physiological conditions, constitutive eNOS activity and production of endothelial nitric oxide (NO) exert essential neurovascular protective functions. In this review, we first discuss the roles of endothelial NO in prevention of neuronal amyloid accumulation and formation of neurofibrillary tangles, hallmarks of Alzheimer disease pathology. Next, we review existing evidence suggesting that NO released from endothelium prevents activation of microglia, stimulates glycolysis in astrocytes, and increases biogenesis of mitochondria. We also address major risk factors for cognitive impairment including aging and ApoE4 (apolipoprotein 4) genotype with focus on their detrimental effects on eNOS/NO signaling. Relevant to this review, recent studies suggested that aged eNOS heterozygous mice are unique model of spontaneous cerebral small vessel disease. In this regard, we review contribution of dysfunctional eNOS to deposition of Aβ (amyloid-β) into blood vessel wall leading to development of cerebral amyloid angiopathy. We conclude that endothelial dysfunction manifested by the loss of neurovascular protective functions of NO may significantly contribute to development of cognitive impairment.
Cerebral Small Vessel Disease–Related Dementia: More Questions Than Answers
Wang, Michael M. , Wang, Michael M , Elahi, Fanny M. , Meschia, James F.

Mayo Clinic

Stroke | February 27, 2023 | Volume: 54 | Issue: 3 | Pages: 648-660

10.1161/strokeaha.122.038265 | PMID 36848423 Get It

Cerebral small vessel disease (CSVD) has emerged as a common factor driving age-dependent diseases, including stroke and dementia. CSVD-related dementia will affect a growing fraction of the aging population, requiring improved recognition, understanding, and treatments. This review describes evolving criteria and imaging biomarkers for the diagnosis of CSVD-related dementia. We describe diagnostic challenges, particularly in the context of mixed pathologies and the absence of highly effective biomarkers for CSVD-related dementia. We review evidence regarding CSVD as a risk factor for developing neurodegenerative disease and potential mechanisms by which CSVD leads to progressive brain injury. Finally, we summarize recent studies on the effects of major classes of cardiovascular medicines relevant to CSVD-related cognitive impairment. Although many key questions remain, the increased attention to CSVD has resulted in a sharper vision for what will be needed to meet the upcoming challenges imposed by this disease.
Update of penetrance estimates in Birt-Hogg-Dubé syndrome
Bruinsma, Fiona , Dowty, James G., Win, Aung Ko , Goddard, Laura C, Agrawal, Prachi , Attinà, Domenico , Bissada, Nabil K., Eisen, Daniel B. , Furuya, Mitsuko , Hansen, Thomas van Overeem , Houweling, Arjan C. , Johannesma, Paul C., Lim, Derek H.K., Lindor, Noralane M. , Luzzi, Valentina , Lynch, Maeve , Maffé, Antonella, Menko, Fred H. , Michels, Guido, Pulido, José S. , Ryu, Jay H. , Sattler, Elke , Steinlein, Ortrud K. , Tucker, Kathy , Beek, Irma van de , Riel, Lore van , Zénone, Thierry, Zompatori, Maurizo, Bondavalli, Davide , I-CONFIRM, Genetic Susceptibility Working Group, Bruinsma, Fiona Jane , Turchetti, Daniela , Maher, Eamonn R , Win, Aung K , Ryu, Jay H , Hansen, Thomas van Overeem , Luise, Monica De , Gasparre, Giuseppe , Genuardi, Maurizio , Gerdes, Anne‐Marie , Lencastre, André , Tomassetti, Sara , Steensel, Maurice A. M. Van , Zompatori, Maurizio , Walsh, Jennifer, Maher, Eamonn R. , Winship, Ingrid , I-CONFIRM, Genetic Susceptibility Working Group

Mayo Clinic

Journal of Medical Genetics | February 27, 2023 | Volume: 60 | Issue: 4 | Pages: 317-326

10.1136/jmg-2022-109104 | PMID 36849229 Get It

Background Birt-Hogg-Dubé (BHD) syndrome is a rare genetic syndrome caused by pathogenic or likely pathogenic germline variants in the FLCN gene. Patients with BHD syndrome have an increased risk of fibrofolliculomas, pulmonary cysts, pneumothorax and renal cell carcinoma. There is debate regarding whether colonic polyps should be added to the criteria. Previous risk estimates have mostly been based on small clinical case series. Methods A comprehensive review was conducted to identify studies that had recruited families carrying pathogenic or likely pathogenic variants in FLCN . Pedigree data were requested from these studies and pooled. Segregation analysis was used to estimate the cumulative risk of each manifestation for carriers of FLCN pathogenic variants. Results Our final dataset contained 204 families that were informative for at least one manifestation of BHD (67 families informative for skin manifestations, 63 for lung, 88 for renal carcinoma and 29 for polyps). By age 70 years, male carriers of the FLCN variant have an estimated 19% (95% CI 12% to 31%) risk of renal tumours, 87% (95% CI 80% to 92%) of lung involvement and 87% (95% CI 78% to 93%) of skin lesions, while female carriers had an estimated 21% (95% CI 13% to 32%) risk of renal tumours, 82% (95% CI 73% to 88%) of lung involvement and 78% (95% CI 67% to 85%) of skin lesions. The cumulative risk of colonic polyps by age 70 years old was 21% (95% CI 8% to 45%) for male carriers and 32% (95% CI 16% to 53%) for female carriers. Conclusions These updated penetrance estimates, based on a large number of families, are important for the genetic counselling and clinical management of BHD syndrome.